Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.63 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.52 |
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | ACLY | P53396 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | CCR9 | P51686 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | UQCRB | P14927 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4649581 | 0.86 | HSD17B2 (0.63) | SLC22A12RXFP1CCR9UQCRBHSD17B2 | |
| SCHEMBL7588697 | 0.85 | PTGES2 (0.74) | PTGES2KMT2AMEN1LMNAMAPT | |
| SCHEMBL4650211 | 0.81 | SLC22A12 (0.63) | SLC22A12PTGES2LMNAKIF11CYP2D6 | |
| SCHEMBL4649590 | 0.81 | SLC22A12 (0.63) | SLC22A12PTGES2KIF11ACLYCYP2D6 | |
| SCHEMBL6553546 | 0.81 | LMNA (0.64) | SLC22A12KMT2AMEN1LMNAMAPT | |
| SCHEMBL14403258 | 0.78 | PTGES2 (0.65) | PTGES2KMT2AMEN1LMNAMAPT | |
| SCHEMBL29540970 | 0.77 | KEAP1 (0.68) | PTGES2KMT2AMEN1LMNAMAPT | |
| SCHEMBL22233891 | 0.77 | KEAP1 (0.68) | PTGES2KMT2AMEN1LMNAMAPT | |
| SCHEMBL8711719 | 0.77 | STAT3 (0.65) | KMT2ALMNAMAPTHTTGAA | |
| SCHEMBL13412104 | 0.77 | SLC22A12 (0.49) | SLC22A12LMNAMAPTRXFP1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101341121-A | Inhibitors of CCR9 activity | NOVARTIS PHARMA AG (CH) | 2009-01-07 | — | — | CN | claimed |
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-11-06 | — | — | US | claimed |
| EP-1966131-A1 | INHIBITORS OF CCR9 ACTIVITY | Novartis Pharma AG (CH) | 2008-09-10 | — | — | EP | claimed |
| WO-2007071443-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | claimed |
| CN-101341121-A | Inhibitors of CCR9 activity | NOVARTIS PHARMA AG (CH) | 2009-01-07 | — | — | CN | disclosed |
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-11-06 | — | — | US | disclosed |
| EP-1966131-A1 | INHIBITORS OF CCR9 ACTIVITY | Novartis Pharma AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071443-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | CCR9, CCR1, CCR4 | SLC22A12 2675/4885PTGES2 2188/4885KMT2A 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.